Do you want to read an article? Please log in or register.
A small-molecule P2RX7 activator promotes anti-tumor immune responses and sensitizes lung tumor to immunotherapy
Lung Cancer
RECOMMENDED
Related content
COMMENTED
Epigenetic prediction of response to anti-PD-1 treatment in non-small-cell lung cancer: a multicentre, retrospective analysis
Lancet Respir Med.
Duruisseaux M, Martínez-Cardús A, Calleja-Cervantes ME, Moran S, Castro de Moura M, Davalos V, Piñeyro D, Sanchez-Cespedes M, Girard N, Brevet M, Giroux-Leprieur E, Dumenil C, Pradotto M, Bironzo P, Capelletto E, Novello S, Cortot A, Copin MC, Karachaliou N, Gonzalez-Cao M, Peralta S, Montuenga LM, Gil-Bazo I, Baraibar I, Lozano MD, Varela M, Ruffinelli JC, Palmero R, Nadal E, Moran T, Perez L, Ramos I, Xiao Q, Fernandez AF, Fraga MF, Gut M, Gut I, Teixidó C, Vilariño N, Prat A, Reguart N, Benito A, Garrido P, Barragan I, Emile JF, Rosell R, Brambilla E, Esteller M
doi: 10.1016/S2213-
RECOMMENDED
Lung CancerPleural DiseasesFurther Publications
Immune checkpoint immunotherapy for non-small cell lung cancer: benefits and pulmonary toxicities
Chest.
Suresh K, Naidoo J, Lin CT, Danoff S
doi: 10.1016/
RECOMMENDED
Lung Cancer
The Impact of Beta Blockers on Survival Outcomes in Patients With Non-small-cell Lung Cancer Treated With Immune Checkpoint Inhibitors
★ 1
Recommended by
Dr Martin Frey, Faculty Member
Clin Lung Cancer.
Oh MS, Guzner A, Wainwright DA, Mohindra NA, Chae YK, Behdad A, Villaflor VM
doi: 10.1016/j.cllc.2020.07.016.
RECOMMENDED
Lung Cancer
Efficacy and Safety of Anti-PD-1 Immunotherapy in Patients Aged ≥ 75 Years With Non-small-cell Lung Cancer (NSCLC): An Italian, Multicenter, Retrospective Study
Clin Lung Cancer.
Luciani A, Marra A, Toschi L, Cortinovis D, Fava S, Filipazzi V, Tuzi A, Cerea G, Rossi S, Perfetti V, Rossi A, Giannetta L, Sala L, Finocchiaro G, Pizzutilo EG, Carelli S, Agustoni F, Cergnul M, Zonato S, Siena S, Bidoli P, Ferrari D
doi: 10.1016/j.cllc.2020.05.004.
Lung Cancer
CCL19-producing fibroblastic stromal cells restrain lung carcinoma growth by promoting local antitumor T-cell responses
J Allergy Clin Immunol.
Cheng HW, Onder L, Cupovic J, Boesch M, Novkovic M, Pikor N, Tarantino I, Rodriguez R, Schneider T, Jochum W, Brutsche M, Ludewig B
doi: 10.1016/j.jaci.2017.12.998.
RECOMMENDED
Lung Cancer
Biomarkers of Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer: Beyond PD-L1
★ 1
Recommended by
Dr Martin Frey, Faculty Member
★ 1
Recommended by
Dr Marcus Hesse, Faculty Member
Clin Lung Cancer
Cabezón-Gutiérrez L, Custodio-Cabello S, Palka-Kotlowska M, Alonso-Viteri S, Khosravi-Shahi P
doi: 10.1016/j.cllc.2021.03.006
RECOMMENDED
Lung Cancer
A Prospective Trial Evaluating the Safety and Systemic Response From the Concurrent Use of Radiation Therapy with Checkpoint Inhibitor Immunotherapy in Metastatic Non-Small Cell Lung Cancer
★ 1
Recommended by
Dr Martin Frey, Faculty Member
★ 2
Recommended by
Dr Marcus Hesse, Faculty Member
Clin Lung Cancer
Mattes MD, Eubank TD, Almubarak M, Wen S, Marano GD, Jacobson GM, Ma PC
doi: 10.1016/j.cllc.2021.01.012
RECOMMENDED
Lung Cancer
Automated chromogenic multiplexed immunohistochemistry assay for diagnosis and predictive biomarker testing in non-small cell lung cancer
Lung Cancer.
Ilie M, Beaulande M, Hamila M, Erb G, Hofman V, Hofman P
doi: 10.1016/j.lungcan.
RECOMMENDED
Lung Cancer
Carboplatin plus etoposide versus topotecan as second-line treatment for patients with sensitive relapsed small-cell lung cancer: an open-label, multicentre, randomised, phase 3 trial
★ 2
Recommended by
Dr Martin Frey, Faculty Member
Lancet Oncol.
Baize N, Monnet I, Greillier L, Geier M, Lena H, Janicot H, Vergnenegre A, Crequit J, Lamy R, Auliac JB, Letreut J, Le Caer H, Gervais R, Dansin E, Madroszyk A, Renault PA, Le Garff G, Falchero L, Berard H, Schott R, Saulnier P, Chouaid C, Groupe Français de Pneumo-Cancérologie 01–13 investigators.
doi: 10.1016/S1470-2045(20)30461-7.